Dr. Rachel Salzman serves as Chief Executive Officer (CEO) at Tovero Bio, a privately held preclinical stage biotech focusing on curative approaches for neuromuscular disorders where toxic gain of function plays a causative role in disease pathology. Prior to joining Tovero, Rachel was Executive Vice President of Portfolio, External Affairs & Development at Alcyone Therapeutics, a precision medicines company advancing therapies in serious neurological disorders by integrating novel delivery technologies with innovative genetic platforms.

Dr. Salzman has been an active member of ASGCT
(American Society of Gene and Cell Therapy) for over 20 years and has served in a leadership capacity including elected membership to the Board of Directors, along with multiple committees and task forces designed to build and enhance the state of gene and cell therapy in both the US and EU.